We recommend further preclinical studies and consideration of clinical investigation of scheduled anti-EGFR therapies combined with taxanes for ESCC patients with tumours expressing high EGFR by IHC and/or EGFR CNG. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.